Thelin

Active Substance: sitaxentan sodium
Common Name: sitaxentan sodium
ATC Code: C02KX03
Marketing Authorisation Holder: Pfizer Ltd.
Active Substance: sitaxentan sodium
Status: Withdrawn
Authorisation Date: 2006-08-10
Therapeutic Area: Hypertension, Pulmonary
Pharmacotherapeutic Group: Antihypertensives

Therapeutic Indication

Treatment of patients with pulmonary arterial hypertension (PAH) classified as WHO functional class III, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension and in pulmonary hypertension associated with connective tissue disease.

The marketing authorisation for Thelin has been withdrawn at the request of the marketing authorisation holder.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.